• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Amarantus Bioscience Holdings, Inc (AMBS)

    -Other OTC
    0.06 Down 0.00(5.55%) Mar 27, 3:59PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Amarantus Bioscience Holdings, Inc
    655 Montgomery Street
    Suite 900
    San Francisco, CA 94111
    United States - Map
    Phone: 415-688-4484
    Fax: 408-852-4427
    Website: http://www.amarantus.com

    Index Membership:N/A
    Full Time Employees:3

    Business Summary 

    Amarantus BioScience Holdings, Inc., a biotechnology company, engages in discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. Its lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is a targeted therapeutic to address the underlying programmed cell death (apoptosis) associated with a range of devastating human disorders with a priority to identify drug able orphan indications, including Retinitis Pigmentosa. The company’s principal products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and Eltoprazine, a small molecule drug candidate, which is used for the treatment of Parkinson’s disease medication Levadopa-Induced Dyskinesia and Adult Attention Deficit Hyperactivity Disorders that is in Phase II clinical trials. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Amarantus Bioscience Holdings, Inc

    Key Executives 
    Mr. Gerald E. Commissiong , 33
    Chief Exec. Officer, Pres and Director
    Dr. John Wesley Commissiong Ph.D., 71
    Chief Scientific Officer, Director and Member of the Scientific Advisory Board
    Mr. Robert Lewis Harris , 71
    Compliance Officer, Independent Director, Chairman of Governance & Nominating Committee, Member of Compensation Committee and Member of Audit Committee
    Mr. Marc E. Faerber , 60
    VP of Financial Operations, Corp. Controller, Treasurer and Sec.
    Mr. Robert E. Farrell J.D., Esq., 65
    Chief Financial Officer
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders